<DOC>
	<DOCNO>NCT02581891</DOCNO>
	<brief_summary>This study aim evaluate optimal use , efficacy , safety Treat-and-Extend regimen aflibercept subject nAMD .</brief_summary>
	<brief_title>Managing Neovascular ( Known `` Wet '' ) Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules 2 mg Intravitreal Aflibercept Injected Eye</brief_title>
	<detailed_description>The T &amp; E dose regimen nAMD emerge preferred regimen many treat physician aim maximize outcome proactively treat subject visit extend treatment interval ( extension criterion meet ) , thus limit visit , monitoring , injection . To day , limit evidence available address question useful interval treat monitoring , differ among subject , retreatment criterion apply achieve long-term desirable outcome real-life practice . This study design evaluate optimal use , efficacy , safety T &amp; E regimen intravitreal aflibercept subject nAMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Men woman â‰¥ 50 year age . Active primary subfoveal CNV lesion secondary nAMD , include juxtafoveal lesion affect fovea evidence FA study eye . Patients polypoidal choroidal vasculopathy retinal angiomatous proliferation eligible participate study , condition capture eCRF . ETDRS BCVA 73 25 letter ( 20/40 20/320 Snellen equivalent ) study eye . The area CNV must occupy least 50 % total lesion . Any prior ocular ( study eye ) systemic treatment surgery nAMD , except dietary supplement vitamin . Any prior concomitant therapy another investigational agent treat nAMD study eye . Prior treatment antiVEGF agent follow : Prior treatment antiVEGF therapy study eye allow Prior treatment antiVEGF therapy fellow eye investigational agent ( approve , e.g . bevacizumab ) within last 3 month first dose study . Such treatment also allow study . Prior treatment approve antiVEGF therapy fellow eye allow . Prior systemic antiVEGF therapy , investigational approve , within last 3 month first dose study , treatment allow study . Total lesion size &gt; 12 disc area ( 30.5 mm2 , include blood , scar neovascularization ) assess FA study eye . Subretinal hemorrhage either 50 % total lesion area , blood fovea 1 disc area size study eye . ( If blood fovea , fovea must surround 270 degree visible CNV ) . Scar fibrosis make &gt; 50 % total lesion study eye . Scar , fibrosis , atrophy involve center fovea study eye . Presence retinal pigment epithelial tear rip involve macula study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neovascular age-related macular degeneration</keyword>
	<keyword>nAMD )</keyword>
</DOC>